<DOC>
	<DOCNO>NCT02607618</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind study efficacy safety iclaprim compare vancomycin treatment skin skin structure infection .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Safety Efficacy Iclaprim Versus Vancomycin ABSSSI : REVIVE-2</brief_title>
	<detailed_description>This multicenter , randomize , double-blind study efficacy safety IV iclaprim compare IV vancomycin . Patients receive either iclaprim vancomycin 5 14 day . Patients evaluate daily early time point ( ETP ) , every 48 72 hour end treatment . Patients also evaluate test cure ( TOC ) visit ( 7 14 day post-EOT ) , Late Follow-Up ( LFU ) visit ( 28 32 day post-first dose ) .</detailed_description>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Iclaprim</mesh_term>
	<criteria>1. write informed consent ; 2 . â‰¥18 year age ; 3. bacterial infection skin lesion size area least 75 cm2 ; 4. major cutaneous abscess , cellulitis/erysipelas , and/or wound infection ; 5. presence purulent seropurulent drainage least three sign symptoms infection ( discharge , erythema , swell , warmth , pain ) . 1. severely impaired arterial blood supply amputation infect anatomical site likely ; 2. infect diabetic foot ulcer ; 3. infect decubitus ulcer ; 4. necrotizing fasciitis gangrene ; 5. uncomplicated skin skin structure infection ; 6. infection associate prosthetic device ; 7. suspect confirmed osteomyelitis ; 8. condition require systemic antimicrobial treatment , prophylaxis , suppression therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>